Tamoxifen (Tmx) was nanoencapsulated in poly(L-lactide) (PLA) nanoparticles.
•
Mean particle size was 155 nm and Tmx encapsulation efficiency was 85%.
•
A prolonged and biphasic Tmx release occurred with 30% released after 120 h.
•
PLA nanoparticles containing Tmx presented a very low hemolysis, but not free Tmx.
•
Tmx nanoparticles exhibited time/concentration-dependent cytotoxicity over HeLa cells.
Abstract
In this study, poly(L-lactide) (PLA) nanoparticles containing Tamoxifen (Tmx) were developed using an emulsion/solvent evaporation method, observing the influence of surfactants and their concentrations on mean particle size and drug entrapment. Nanoparticles were characterized in terms of size, morphology, polydispersity, interaction drug-polymer and in vitro drug release profile. Cytotoxicity over erythrocytes and tumor cells was assessed. The optimized formulation employed as surfactant 1% polyvinyl alcohol. Mean particle size was 155 ± 4 nm (n = 3) and Tmx encapsulation efficiency was 85 ± 8% (n = 3). The in vitro release profile revealed a biphasic release pattern diffusion-controlled with approximately 24% of drug released in 24 h followed by a sustained release up to 120 h (30% of Tmx released). PLA nanoparticles containing Tmx presented a very low index of hemolysis (less than 10%), in contrast to free Tmx that was significantly hemolytic. Tmx-loaded PLA nanoparticles showed IC50 value 2-fold higher than free Tmx, but considering the prolonged Tmx release from nanoparticles, cytotoxicity on tumor cells was maintained after nanoencapsulation. Thus, PLA nanoparticles are promising carriers for controlled delivery of Tmx with potential application in cancer treatment.
